Skip to content

MDMA research published in 2026

Page 5 of 8: studies 81 to 100 of 151, newest first. Back to the MDMA overview

Studies

Psychedelic Use and Missed Needed Mental Health Treatment: Gender Differences in Unmet Perceived Need for Care

Psychoactives May 12, 2026 Sean M. Viña

While prior research links psychedelic use to improved psychological outcomes, less is known about whether psychedelic exposure relates to engagement with formal mental health care when treatment is recognized as needed. Using publicly available, de-identified pooled data from the National Survey on Drug Use and Health (2008–2019), this study examines whether lifetime psychedelic use is...

DOI: 10.3390/psychoactives5020014 (opens in new tab) MDMA Odds Psychological distress Mental distress +7

Development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET): a Delphi study.

BMJ Open May 11, 2026 Julia Colcott, Alexandre A. Guerin, Olivia Carter et al.

Despite growing interest in the therapeutic potential of 3,4-methylenedioxymethamphetamine (MDMA), no targeted measure to systematically assess side effects of MDMA-assisted psychotherapy (MDMA-AP) exists. Our aim was to develop an MDMA-Assisted Psychotherapy Side Effects Tool (M-SET) to capture side effects over the course of MDMA-AP. Informed by a systematic review and a review of other...

R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential.

ACS Chemical Neuroscience May 6, 2026 Maxemiliano V. Vargas, Cassandra J. Hatzipantelis, Lee E. Dunlap et al.

Recent clinical evidence suggests that racemic 3,4-methylenedioxymethamphetamine (MDMA) might be useful for treating a range of neuropsychiatric diseases including post-traumatic stress disorder (PTSD) and depression. However, concerns about its abuse potential stemming from its monoamine releasing properties have hampered its clinical development. Thus, safer analogues of racemic MDMA with...

Glutathione as a Potential Neuroprotectant Against MDMA-Induced Oxidative Stress, Neuroinflammation, and Apoptosis in the Rat Brain.

Neurochemical Research May 6, 2026 Oyedayo Phillips Akano, Goodness Olatinwo, Moses Agbomhere Hamed et al.

3,4-Methylenedioxymethamphetamine (MDMA), widely misused for its euphoric and stimulant properties, induces overt neurotoxicity in rodents and non-human primates and is associated with profound neurochemical and structural brain alterations. Its deleterious effects are primarily mediated through oxidative stress, neuroinflammatory responses, and apoptotic pathways. Glutathione, a crucial...

DOI: 10.1007/s11064-026-04764-0 (opens in new tab) Full text (opens in new tab) Ecstasy Antioxidant therapy Chronic oral exposure Hippocampal injury +2

MDMA-Assisted Therapy Randomized Controlled Trial Incremental Effects Systematic Review and Meta-Analysis

medRxiv Preprint Server May 5, 2026 Nicholas C. Borgogna, D. Drew Whittington, Tyler Owen et al. preprint

Mental illness poses a substantial global burden, yet existing psychotherapies and psychopharmacologies often produce limited outcomes. Psychedelic-assisted therapies have re-emerged as potential transdiagnostic interventions. In particular, 3,4-methylenedioxymethamphetamine–assisted therapy (MDMA-AT) has generated interest for its rapid psychological effects and potential to enhance...

A Systematic Review of MDMA’s Effects on Social Functioning in Placebo-Controlled Trials

May 4, 2026 Victoria Burmester, Laura Aggett, David Nutt et al. preprint

Background3,4-Methylenedioxymethamphetamine (MDMA) is associated with distinctive prosocial and empathogenic effects, yet the consistency and scope of its impact on social functioning in humans remain unclear. Although numerous placebo-controlled studies have examined MDMA’s acute social effects, findings vary widely across subjective and behavioural domains.MethodsWe conducted a systematic...

DOI: 10.31234/osf.io/sgdau_v1 (opens in new tab) MDMA Prosocial behavior Social cognition Context archaeology +18

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults

American Journal of Preventive Medicine May 4, 2026 Kevin H. Yang, Nora Satybaldiyeva, Wayne Kepner et al. 1 citation

IntroductionMicrodosing involves consuming low doses of psychoactive substances, typically between 1/5th and 1/20th of a recreational dose. Despite increasing public attention to cannabis and psychedelics amid evolving drug policies, epidemiologic data on microdosing remain limited.MethodsA cross-sectional, web-based survey (Characterizing the Epidemiology of Cannabidiol Use Survey) of 1,523...

Severe Hyponatremic Encephalopathy Induced by Unsupervised "Therapeutic" 3,4-Methylenedioxymethamphetamine Use in a 55-Year-Old Woman: A Diagnostic Pitfall.

Cureus May 1, 2026 Pierre-Henri Woitrin, Pascale Lievens

While the clinical archetype of 3,4-methylenedioxymethamphetamine (MDMA) toxicity is traditionally associated with young individuals in nightlife environments, particularly in nightclubs and rave settings, its emerging role in therapeutic research may contribute to increasing unsupervised use. As MDMA gains mainstream attention for its potential mental health benefits, particularly for...

DOI: 10.7759/cureus.108360 (opens in new tab) Full text (opens in new tab) 4-Methylenedioxymethamphetamine MDMA Acute hyponatremia Diagnostic bias Emergency medicine +2

Deep venous thrombosis of the axillary and humeral veins following Ecstasy use: A case report

World Journal of Advanced Research and Reviews April 30, 2026 Khalfy Y. El, Chhaiba Y. Ould, Andaloussi Y. El

Background: 3,4-methylenedioxymethamphetamine (MDMA), or "Ecstasy," is a semi-synthetic stimulant and hallucinogen widely used recreationally. While known for producing euphoria, it is associated with severe medical complications including serotonin syndrome, rhabdomyolysis, and multi-organ failure. Although MDMA is known to cause various vascular and muscular lesions, deep venous thrombosis...

The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder

Preprints.org April 29, 2026 Stefano Marini, Domenico de Berardis preprint

Psychedelic drugs are serotonergic hallucinogens that can be divided into two types: naturally occurring (psilocybin, psilocin, and N,N-dimethyltryptamine) and synthetic (LSD, MDMA, 2,5-dimethoxy-4-iodoamphetamine, and ketamine). Psychedelics generally work on 5-hydroxytryptamine receptors and might be useful in cognitive enhancement, brain connectivity, neuroplasticity, and neuronal...

DOI: 10.20944/preprints202604.1998.v1 (opens in new tab) Addiction Autism spectrum disorder Hallucinogen Psychopathology +4

Fusing Specialized Surveys of Rare Populations to Larger Surveys for Generalized Inference: Cross-Sectional Survey Study.

Journal of Medical Internet Research April 27, 2026 Karilynn M Rockhill, Elizabeth A Bemis, Nicole Schow et al. 2 citations

Mainstays of pharmacoepidemiology are large, representative, behavioral surveys, which focus on many drugs with few detailed behaviors. Smaller, targeted studies measure drug-specific patterns but without explicit generalizability assumptions; the evidence generated is narrow. In this cross-sectional survey study, we outline an estimation framework based on data fusion and combine two surveys:...

Protective effects of vitamin E and quercetin against MDMA-induced cardiac and hematological dysfunction in male wistar rats.

Pflügers Archiv: European Journal of Physiology April 23, 2026 Ayodeji Folorunsho Ajayi, David Tolulope Oluwole, Moses Agbomhere Hamed et al.

3,4-Methylenedioxymethamphetamine (MDMA), a synthetic psychoactive amphetamine derivative widely abused as the recreational drug “ecstasy,” is associated with oxidative stress–mediated cardiotoxicity and hematological disturbances. Despite documented antioxidant properties of quercetin and vitamin E individually, limited evidence exists regarding their combined protective efficacy against...

DOI: 10.1007/s00424-026-03169-w (opens in new tab) Full text (opens in new tab) Cardiotoxicity Hematology, MDMA Oxidative stress Quercetin +1

Substance use predictors of arrest and self-reported criminal behavior in the United States: The role of psychedelics and rarely used drugs

Journal of Psychopharmacology April 16, 2026 Jesse J. Norris 1 citation

Background: Little research investigates the role of rarely used drugs in criminal offending. Moreover, given research suggesting that psychedelics reduce criminal offending, more research is needed to further document connections between psychedelics and crime. Aim: This study examines the role of rarely used drugs in criminal behavior and extends previous research on psychedelics by...

DOI: 10.1177/02698811261436577 (opens in new tab) MDMA Substance use Criminal behavior Hallucinogen +5

Effects of MDMA treatment and cessation on sexual behaviour and testicular functions in male sprague-dawley rats.

BMC Pharmacology and Toxicology April 11, 2026 O O Obembe, E T George, R A Mustapha et al.

BACKGROUND: 3,4-Methylenedioxymethamphetamine (MDMA) is a psychostimulant known for its social and empathogenic effects. However, its long-term impact on sexual performance and reproductive functions remain controversial. OBJECTIVE: In this study, the effects of chronic MDMA exposure and subsequent withdrawal on sexual behaviour, reproductive hormones, sperm parameters, oxidative stress,...

DOI: 10.1186/s40360-026-01131-1 (opens in new tab) Full text (opens in new tab) MDMA Inflammation Oxidative stress Reproductive hormones +1

Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use

Molecular Psychiatry April 8, 2026 Johannes G. Ramaekers, Kim P. C. Kuypers, Franz X. Vollenweider 1 citation

MDMA's history spans military experimentation, recreational use, and clinical trials for PTSD treatment, reflecting both promise and controversy. While studies in heavy users suggested possible neurotoxicity, evidence remains inconclusive. Clinical trials show that one to three sessions of MDMA-assisted psychotherapy can alleviate PTSD symptoms, yet regulators have criticized inadequate...

DOI: 10.1038/s41380-026-03602-7 (opens in new tab) Full text (opens in new tab) Neurocognitive Profiling computer programming Medline Clinical trial +2

Ecstasy (MDMA) for social anxiety in autism: a specialized application of empathogen therapy

Annals of Medicine and Surgery April 6, 2026 Mahnoor Sheikh, Zaibunnisa Bilal, Syeda Habiba Fatima et al.

To the Editor, Autism spectrum disorder (ASD) is a neurodevelopmental state in which there are early emerging problems in social communication along with fixed behavior patterns. Social difficulties in ASD are characterized by difficulty in interpretation of interpersonal signals such as facial expressions, tone of voice, and body language. Individuals with ASD often present with social...

DOI: 10.1097/ms9.0000000000004936 (opens in new tab) Ecstasy Social anxiety Social skills Social inhibition +14

The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database.

Journal of Psychopharmacology April 6, 2026 Kirsten L Rock, Paul Rees, David Morgan et al.

3,4-methylenedioxymethamphetamine (MDMA) is being investigated as a new therapy for post-traumatic stress disorder (PTSD). With antidepressants as the first-line pharmacotherapy for PTSD, it is important to understand any drug-drug interactions between antidepressants and MDMA. This study aimed to investigate the association between antidepressant use and MDMA fatality using a drug-death...

3,4-Methylenedioxymethamphetamine: From Dangerous Party Drug to Potential Therapeutic Agent

Quality in Sport April 5, 2026 Magdalena Ostaszewska, Milena Majchrzyk, Damian Zienkiewicz et al.

Introduction and aim of the study: 3,4-methylenedioxymethamphetamine (MDMA) is a stimulant drug with widespread consumption. It is used mainly in recreational settings, due to its ability to induce various pleasurable, mood-enhancing effects. Prolonged and excessive MDMA misuse can lead to multiple negative outcomes ranging from cognitive dysfunction or emotional dysregulation to severe...

Stimulants: Cocaine, Amphetamines, and MDMA

Drugs April 1, 2026 Martha S. Rosenthal

This chapter examines the pharmacology, effects, and history of stimulants, focusing on cocaine, amphetamines, MDMA, and other related substances. Cocaine plays a significant role as a medical marvel and recreational drug, available in forms such as powder and crack, which differ in potency and methods of use. Amphetamines, initially praised for their therapeutic benefits, gain attention for...

Market approval and the right to health: a human rights perspective on MDMA-assisted therapy

JME Practical Bioethics April 1, 2026 Christoph Bublitz

The application for MDMA-assisted therapy (MDMA-AT) and its rejection by the FDA in 2024 prompted a debate about ethical aspects in drug regulation. This paper examines central issues raised in that debate through the lens of human rights, especially the right to health. It argues that drug approval decisions must take into account the multipolar constellation of and dependencies between...